A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats
- 22 September 2015
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 42 (6) , 721-733
Abstract
A population PK model was developed in order to simultaneously describe citalopram and its major metabolite, n-desmethyl citalopram, plasma concentrations in two different strain of rats after intravenous (IV) and oral (PO) administration of citalopram. Citalopram was administered to Sprague–Dawley (SD) rats at doses: 0.3, 1, 3, and 10 mg/kg IV and 10 mg/kg PO. The compound was dosed orally to Wistar rats at doses: 0.3, 1, 3, 10, 30 and 60 mg/kg. Plasma samples were collected for citalopram and metabolite. Pharmacokinetic analyses were conducted using NONMEM 7.2. Values below the quantification limit (BLQ <0.1 ng/mL) were included in the analyses and treated as censored information. The disposition of citalopram was best described by a 3-compartment model and its desmethyl metabolite by a 2-compartment model. Several models for the absorption rate were explored (e.g. first, zero order and combined first and zero order absorption, Michaelis–Menten, lag time) in combination with dose and/or time dependent covariate effects. Dose dependent oral bioavailability properties were also identified in this analysis. Citalopram IV clearance and metabolite formation rate were adequately described as linear processes. Metabolite clearance was adequately described using a Michaelis–Menten clearance with different parameters depending on the strain. This analysis demonstrates a very complex absorption/metabolism process explaining the highly non-linear pharmacokinetics observed across all the doses. This is the first combined parent/metabolite population PK analysis in both SD and Wistar rats over a wide range of IV and PO dosages for citalopram, a compound that exhibits highly nonlinear oral pharmacokinetics in rats.Keywords
This publication has 13 references indexed in Scilit:
- How to combine non-compartmental analysis with the population pharmacokinetics? A study of tobacco smoke's influence on the bioavailability of racemic citalopram in ratsPharmacological Reports, 2013
- Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification SystemBritish Journal of Clinical Pharmacology, 2010
- Enantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LC‐MS/MS: Application to pharmacokineticsChirality, 2007
- Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studiesJournal of Pharmacokinetics and Pharmacodynamics, 2007
- Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat CuesBiological Psychiatry, 2006
- Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programmingComputer Methods and Programs in Biomedicine, 2004
- The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptineBiological Psychiatry, 2004
- Citalopram: a comprehensive reviewExpert Opinion on Pharmacotherapy, 2001
- Pharmacokinetics of selective serotonin reuptake inhibitorsPharmacology & Therapeutics, 2000
- Pharmacology and pharmacokinetics of citalopram and other SSRIsInternational Clinical Psychopharmacology, 1996